November 20, 2014 9:58 PM ET


Company Overview of SARcode Bioscience Inc.

Company Overview

SARcode Bioscience Inc. develops small molecule compounds for the treatment of ophthalmic and dermatologic inflammations caused due to T-cells. It involves in the development of a lymphocyte function-associated antigen-antagonists for the treatment of T-cell mediated inflammatory diseases. The company was founded in 2006 and is based in Brisbane, California. As of April 17, 2013, SARcode Bioscience Inc. operates as a subsidiary of Shire plc.

1000 Marina Boulevard

Suite 250

Brisbane, CA 94005

United States

Founded in 2006





Key Executives for SARcode Bioscience Inc.

Chief Executive Officer
Age: 63
Co-Founder and President
Co-Founder and Director
Chief Financial Officer and Vice President of Business Development
Age: 46
Partner and Director
Compensation as of Fiscal Year 2014.

SARcode Bioscience Inc. Key Developments

SARcode Bioscience, Inc. Presents at Leerink Swann Global Healthcare Conference, Feb-13-2013 11:30 AM

SARcode Bioscience, Inc. Presents at Leerink Swann Global Healthcare Conference, Feb-13-2013 11:30 AM. Venue: Waldorf Astoria Hotel, New York, New York, United States. Speakers: Quinton Oswald, Chief Executive Officer.

SARcode Bioscience, Inc. Announces Second Pivotal Study of Lifitegrast Ophthalmic Solution

SARcode Bioscience, Inc. announced that the initial subject has been enrolled in a second pivotal Phase 3 clinical efficacy study (OPUS-2) of lifitegrast ophthalmic solution 5.0%. OPUS-2 will assess the efficacy and safety of lifitegrast in the treatment of dry eye disease. Approximately 700 subjects will be randomized to receive lifitegrast or placebo twice daily over 12 weeks. The co-primary endpoints of the study are inferior corneal fluorescein staining score and eye dryness. Lifitegrast has been studied in over 900 subjects to date and has demonstrated statistical significance in several signs and symptoms of dry eye disease. Dose-dependent improvements were observed in both corneal and conjunctival staining, key indicators of ocular surface health. Lifitegrast also improved eye dryness and ocular discomfort, the two most commonly reported symptoms of dry eye Lifitegrast was well tolerated and there were no unexpected or serious ocular adverse events. The most commonly reported ocular adverse events were irritation and pain upon initial instillation of lifitegrast, and were generally mild and transient in nature. The results from OPUS-1 and OPUS-2, along with results from an ongoing year-long safety study called SONATA, will support a planned New Drug Application.

Similar Private Companies By Industry

Company Name Region
OmegaGenesis Corporation United States
Fe3 Medical, Inc. United States
BioBrite United States
TimTec, Inc. United States
Clarion Research Group, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SARcode Bioscience Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at